GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Capex-to-Operating-Income

NKGen Biotech (NKGen Biotech) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

NKGen Biotech's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-7.62 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


NKGen Biotech Capex-to-Operating-Income Historical Data

The historical data trend for NKGen Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Capex-to-Operating-Income Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, NKGen Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Capex-to-Operating-Income falls into.



NKGen Biotech Capex-to-Operating-Income Calculation

NKGen Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.048) / -29.746
=N/A

NKGen Biotech's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -7.621
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech  (NAS:NKGN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


NKGen Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.